A long-term clinical trial showed significant results when it comes to an experimental drug manufactured by Eli Lilly to be used to treat Alzheimer’s disease. And researchers hope that more good news is on the way on this front.

Far Rockaway Center for Rehabilitation and Nursing has a look at the results of this promising clinical trial.

A Potential Breakthrough in Alzheimer’s Research

Not only is there no cure for Alzheimer’s disease, there’s also no real reliable course of treatment for the fatal disease. But drug company Eli Lilly announced the results of a study that found the drug, called donanemab, had slowed the progression of Alzheimer’s by 32% compared to a placebo.

The study followed 257 people over a 76-week period; 131 people took the drug, while 126 were given a placebo.

So over an 18-month period, those taking the drug had a six-month slower progression. It may not sound like much, but for a disease that doesn’t have much in the way of treatments, it’s encouraging news for doctors and families of those suffering.

“That’s six more months of better cognition, better memories, better enjoyable times with your family,” Maria Carillo, chief science officer of the Alzheimer’s Association, said in a press release.

How Does the Drug Work?

Eli Lilly said the drug works by targeting a hard plaque made by the protein in the brain that it’s believed Alzheimer’s develops from.

Researchers say  there are several other drugs either in development or going through clinical trials that are hopeful to, in combination with donanemab, change the way doctors look at and treat Alzheimer’s disease.

To learn more about Far Rockaway Center for Rehabilitation and Nursing and all of the services they offer, visit http://far-rockaway-center.facilities.centershealthcare.org/.